Wanbury Limited (WANBURY) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Wanbury Limited stock ₹364, price ₹178, upside +104.3%, quality 47 out of 100. Rating: strongly undervalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Wanbury Limited
WANBURY · NSECheap (51% below fair value), but weak company and falling price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range ₹34.15 – ₹344.75 · fair‑value band ₹254.60 – ₹472.31 · the ₹178.03 price screens below the ₹363.71 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Wanbury is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally.
Show moreShow less
The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition.
It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004.
Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Stock analysis
Wanbury Limited (WANBURY) currently trades at ₹178.03, while our model-based Fair Value estimate is ₹363.71, implying the stock looks roughly 51% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹363.71 per share, and 8 of the 14 models we run sit above the ₹178.03 price.
Bear case: the Economic Profit group reads lowest at ₹121.55, and 6 of the 14 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹254.60 (bear) to ₹472.31 (bull), the price of ₹178.03 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Wanbury Limited reported revenue of ₹6.5B in FY2026 versus ₹5.1B in FY2022, a compound +6.2%/yr. Reported net income was ₹661M in FY2026, compounding −5.1%/yr from FY2022.
Key figures
Market cap ₹6.2B (≈ $66.1M) Micro · P/E ratio 10.9 · P/S ratio 0.92 · EPS (TTM) ₹16.28 · Net margin 7.4% · Return on equity 37.4% · Return on assets (EBIT) 12.1% (5-year average) · Operating margin 11.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 104%, WANBURY screens cheaper than that median.
Fair Value models
All 14 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Watch WANBURY, get fair value alerts →
Compare Wanbury Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Fair value gap by industry
- Return on assets by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs WANBURY |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs WANBURY |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs WANBURY |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs WANBURY |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs WANBURY |
| Galderma Group GALD | CHF 191.00 | CHF 112.30 | −41% | vs WANBURY |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs WANBURY |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs WANBURY |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs WANBURY |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs WANBURY |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Wanbury Limited (WANBURY) overvalued or undervalued?
What is the fair value of WANBURY?
What is the quality score of WANBURY?
What is the price target for Wanbury Limited (WANBURY)?
What is the Wanbury Limited stock forecast for 2026?
What is the revenue of Wanbury Limited (WANBURY)?
What is the intrinsic value of Wanbury Limited (WANBURY)?
Is Wanbury Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of WANBURY?
How much is Wanbury Limited worth?
What do the bullish and bearish scenarios say about WANBURY?
What is the P/E ratio of WANBURY?
How solid is the balance sheet of Wanbury Limited (WANBURY)?
How far is WANBURY from its 52-week high?
Which stocks are comparable to Wanbury Limited?
Is Wanbury Limited stock attractive at the current price?
How is the fair value of WANBURY calculated?
Is it still worth investing in stocks now?
What is the share price of Wanbury Limited (WANBURY)?
What should I pay attention to with Wanbury Limited right now?
Key figures of Wanbury Limited
How large is the market capitalisation of Wanbury Limited (WANBURY)?
What is the P/S ratio of Wanbury Limited (WANBURY)?
What are the earnings per share of Wanbury Limited (WANBURY)?
What is the net margin of Wanbury Limited (WANBURY)?
What is the return on equity of Wanbury Limited (WANBURY)?
What is the EBIT return on assets of Wanbury Limited (WANBURY)?
What is the operating margin of Wanbury Limited (WANBURY)?
How fast is revenue growing at Wanbury Limited (WANBURY)?
How fast are earnings growing at Wanbury Limited (WANBURY)?
How much free cash flow does Wanbury Limited (WANBURY) generate?
How much net debt does Wanbury Limited (WANBURY) carry?
Watch Wanbury Limited in the live analysis
One click puts Wanbury Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.